CTI Plans To Spin Off Systems Medicine As Pharmacogenomics Company Apana
This article was originally published in The Pink Sheet Daily
Executive Summary
New firm’s management team is looking for pharma partners to validate its expertise, attract venture funding while parent CTI struggles to stay in business.
You may also be interested in...
CTI Bags Cash, Turns Its Back On Zevalin
Buyer Spectrum downplays supplemental BLA delay in front-line non-Hodgkins lymphoma.
J&J Advances Pipeline With Yondelis, Carisbamate Filings
Company is on track to achieve goal of filing seven to 10 new products from the beginning of 2008 through end of 2010, CEO Weldon says.
Cell Therapeutics Gets In The Groove With Systems Medicine Acquisition
Johnson & Johnson’s Yondelis is in competition with Systems Medicine’s brostallicin to become first minor groove binding agent on the market.